Marc Garfield, DO
Family Medicine · Philadelphia, PANPI 1407899586
Payments from drug & device makers
Across 194 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$547
- GSK$431
- Novo Nordisk$271
- AbbVie$257
- Boehringer Ingelheim$251
- Pfizer$215
- plus $1K from 26 others
What the payments were for
- Food & beverage$3,27697%
- Education$993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $547 |
| GSK | 28 | $431 |
| Novo Nordisk | 17 | $271 |
| AbbVie(2 entities) | 14 | $257 |
| Boehringer Ingelheim | 16 | $251 |
| Pfizer | 17 | $215 |
| Astellas Pharma US Inc | 4 | $146 |
| Amgen | 7 | $134 |
| Lilly USA, LLC | 7 | $127 |
| Merck | 8 | $106 |
| Sumitomo Pharma America, Inc. | 5 | $101 |
| Amarin Pharma, Inc. | 7 | $99 |
| Daiichi Sankyo Inc. | 3 | $73 |
| Braeburn Inc. | 3 | $72 |
| Sanofi Pasteur Inc. | 5 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $51 |
| Supernus Pharmaceuticals, Inc. | 4 | $47 |
| Kvk-tech, Inc. | 1 | $45 |
| Indivior Inc. | 2 | $41 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Gilead | 2 | $33 |
| Agios Pharmaceuticals, Inc. | 1 | $30 |
| Ironwood Pharmaceuticals, Inc | 2 | $29 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| Abbott | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Assertio Therapeutics, Inc. | 1 | $11 |
How this compares
$3,375 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 14 | $113,407 |
| OzempicSemaglutide | 64 | $94,774 |
| JardianceEmpagliflozin | 52 | $82,323 |
| TrulicityDulaglutide | 58 | $74,162 |
| FarxigaDapagliflozin Propanediol | 41 | $49,471 |
| XareltoRivaroxaban | 23 | $37,687 |
| JanumetSitagliptin Phos/Metformin Hcl | 29 | $36,264 |
| JanuviaSitagliptin Phosphate | 24 | $32,019 |
| EliquisApixaban | 21 | $22,610 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 18 | $20,120 |
| EntrestoSacubitril/Valsartan | 13 | $12,981 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $10,719 |
| Omega-3 Acid Ethyl Esters | 85 | $9,557 |
| Atorvastatin Calcium | 639 | $7,997 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $271 | $94,77464 claims |
| Boehringer IngelheimJardiance | $251 | $82,32352 claims |
| Lilly USA, LLCTrulicity | $127 | $74,16258 claims |
| MerckJanumet, Januvia | $106 | $68,28253 claims |
| AstraZenecaFarxiga, Symbicort | $547 | $52,62654 claims |
| PfizerEliquis | $215 | $22,61021 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $431 | $17,84029 claims |
| Astellas Pharma US IncMyrbetriq | $146 | $5,69914 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $24 | $5,37340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Philadelphia
- Daniel LinPhiladelphia$392K
- Glenn RosenPhiladelphia$367K
- Christopher ChambersPhiladelphia$350K
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.